It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

HOW DOES ACC® WORK?

ACC® is a mucolytic1-3

ACC® contains an active ingredient called acetylcysteine (uh-see-tuhl-si-steen).1-4 Acetylcysteine is a popular mucolytic;5,6 a type of medication that breaks down mucus.1-3,5 This ingredient works to change the consistency of mucus (snot) and phlegm, making it thinner and less sticky.1-3,7 It does this by breaking down the bonds holding the mucus and phlegm together.1-3,7

Taking a mucolytic makes it easier to cough up or blow out excess mucus, which leaves your lungs, sinuses or nasal passages clearer.7,8

available as range

A choice of products for the whole family1-3

Choose the ACC® that works for you:

  • ACC® 600 effervescent tablets (1-a-day) are suitable for adults and children from the age of 14.1
  • ACC® 600 Oral Powder (1-a-day), No water needed, is suitable for adults.1
  • ACC® Oral Solution is suitable for adults and children from the age of 2.2
  • ACC® 200 effervescent tablets are suitable for adults and children from the age of 2.3
all range image

 

Did you know? ACC®  also has antioxidant properties.1-3,9

Mucolytics help with the symptoms of colds, flu and allergies7,8,10

ACC® can help you fight the Snotties and Phlegmings1-3 in any season.11-13 A wet cough and congested sinuses are symptoms caused by the extra phlegm and mucus your body produces when you’re struggling with a cold, flu or allergies.7,8,10 Mucolytic medication can help to relieve these symptoms all year round.7,8,10

Did you know? Clearing the mucus and phlegm from your sinuses, nasal passages and lungs can also help to prevent a more serious infection from developing there.7,14

 

ACC® 600 effervescent tablets, ACC® 600 Oral Powder, ACC® Oral Solution and ACC® 200 are registered by the South African Health Products Regulatory Authority (SAHPRA) in South Africa. For more information, including interactions and safety precautions, read the ACC® product leaflets.

References
  1. Sandoz SA (Pty) Ltd. ACC® 600 Professional information. V1.0 (02/11/2021), approved 26 October 2021 (oral powder) and 02 November 2021 (effervescent tablets).
  2. Sandoz SA (Pty) Ltd. ACC® 20 mg/ml ORAL SOLUTION Professional information. V1 (07/10/2021), approved 05 October 2021.
  3. Sandoz SA (Pty) Ltd. ACC® 200 Professional information. V10 (16/08/2022), approved 08 July 2020.
  4. How to pronounce acetylcysteine - Google search. Accessed June 10, 2021. https://www.google.com/search?q=how+to+pronounce+acetylcysteine&rlz=1C1LOQA_enZA752ZA760&oq=how+to+pronounce+acetylceistine&aqs=chrome.1.69i57j0i13j0i22i30j0i390l4.28870j0j15&sourceid=chrome&ie=UTF-8.
  5. Morice A, Kardos P. Comprehensive evidence-based review on European antitussives. BMJ Open Resp Res. 2016;3(1):e000137.
  6. Sandoz SA (Pty) Ltd. Data on file. TPM data. February, 2023.
  7. Kryukov AI, Turovsky AB, Izotova GN, et al. Treatment of acute sinusitis. Russian Medical Journal. 2012;9:458-488.
  8. Zaitseva OV. Rational choice of mucolytic therapy in treatment of respiratory diseases in children. Russian Medical Journal. 2009;17(19):1217-1221.7. Database of medicine prices, 28 Dec 2020.xlsx.
  9. Aldini G, Altomare A, Baron G, et al. N-acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why. Free Radical Research. 2018;52(7):751-762.
  10. What is mucus? Learn how to get rid of it. MedicineNet. Accessed May 31, 2021. https://www.medicinenet.com/what_is_mucus/article.htm.
  11. Price RHM, Graham C, Ramalingam S. Association between viral seasonality and meteorological factors. Sci Rep. 2019;9(1):929.
  12. Green RJ, Davis G, Price D. Concerns of patients with allergic rhinitis: the allergic rhinitis care programme in South Africa. Primary Care Respiratory Journal. 2007;16(5):299-303.
  13. Green RJ, Zar HJ, Jeena PM, et al. South African guideline for the diagnosis, management and prevention of acute viral bronchiolitis in children. South African Medical Journal. 2010;100(5):320.
  14. Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest. 2002;109(5):571-577.

 

Sidebar References
  1. Sandoz SA (Pty) Ltd. ACC® 600 Professional information. V1.0 (02/11/2021), approved 26 October 2021 (oral powder) and 02 November 2021 (effervescent tablets).
  2. Sandoz SA (Pty) Ltd. ACC® 20 mg/ml ORAL SOLUTION Professional information. V1 (07/10/2021), approved 05 October 2021.
  3. Sandoz SA (Pty) Ltd. ACC® 200 Professional information. V10 (16/08/2022), approved 08 July 2020.

 

[S1] ACC® 20 mg/ml Oral Solution. Reg. No.: 48/10.3/0261. Composition: Each 1 ml of ACC 20 mg/ml ORAL SOLUTION contains 20 mg acetylcysteine. ATC Code: R05C B01.

[S1] ACC® 200 (effervescent tablets). Reg. No.: 29/10.2.2/0753. Composition: Each ACC 200 effervescent tablet contains: 200 mg acetylcysteine. Pharmacological Classification: A10.3 Medicines acting on the respiratory system – other.

[S1] ACC® 600 (effervescent tablets). Reg. No.: 45/10.3/0229. Composition: Each effervescent tablet contains 600 mg acetylcysteine. [S1] ACC® 600 ORAL POWDER. Reg. No.: 51/10.3/0816. Composition: Each sachet contains 600 mg of acetylcysteine. ATC Code: R05CB01.

For full prescribing information refer to the Sandoz Professional Information approved by the South African Health Products Regulatory Authority (SAHPRA).

Contact Us
Sandoz SA (Pty) Ltd, Reg. No. 1990/001979/07,
Magwa Crescent West,
Waterfall City,
Jukskei View,
Midrand,
2090.
Tel: +27 (11) 347 6600.
SANCAL Customer Call Centre: 0861 726 225.
Reporting of AEs: 
https://pvi1j.solutions.iqvia.com or [email protected]